dalteparin has been researched along with Cardiovascular Diseases in 29 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 9.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an ≈30% reduction in fatal or irreversible ischemic or bleeding events compared with standard-duration enoxaparin." | 5.24 | Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. ( Arbetter, D; Chi, G; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, R; Jain, P; Korjian, S; Lopes, RD, 2017) |
| " In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens." | 5.15 | Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. ( Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Caravita, T; Carella, AM; Cavo, M; Cellini, C; Crippa, C; Elice, F; Evangelista, A; Galli, M; Gentilini, F; Magarotto, V; Marasca, R; Montefusco, V; Morabito, F; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Polloni, C; Pulini, S; Ria, R; Romano, A; Rossi, D; Tacchetti, P; Tosi, P; Zamagni, E; Zambello, R, 2011) |
| "Enoxaparin is noninferior to UFH+phenprocoumon for prevention of ischemic and embolic events, bleeding complications, and death in TEE-guided cardioversion of atrial fibrillation." | 5.11 | Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) ( Daniel, WG; Geller, C; Hanrath, P; Hofmann, T; Lehmacher, W; Mügge, A; Nixdorff, U; Schmidt-Lucke, C; Schmidt-Lucke, JA; Sehnert, W; Stellbrink, C, 2004) |
| "(1) Aspirin reduces acute-phase mortality after myocardial infarction, and also reduces the risk of myocardial infarction and death in patients with unstable angina." | 3.70 | Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention. ( , 2000) |
| "Bleeding was predominantly gastrointestinal or intracranial." | 2.82 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. ( Albaladejo, P; Beyer-Westendorf, J; Bronson, MD; Cohen, AT; Conley, PB; Connolly, SJ; Crowther, M; Curnutte, JT; Eikelboom, JW; Gibson, CM; Gold, A; Goodman, S; Leeds, J; Lim, WT; Lopez-Sendon, J; Lu, G; Meeks, B; Middeldorp, S; Milling, TJ; Nakamya, J; Schmidt, J; Siegal, DM; Verhamme, P; Wiens, BL; Zotova, E, 2016) |
| "Enoxaparin dosage for obese patients and patients with renal impairment remains controversial." | 2.71 | Dosage of enoxaparin among obese and renal impairment patients. ( Almanric, K; Bazinet, A; Blais, N; Brunet, C; Caron, S; Lalonde, L; Martineau, J; Turcotte, I, 2005) |
| "Dabigatran etexilate is an oral direct thrombin inhibitor that has been approved by the US Food and Drug Administration for the prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation." | 2.47 | Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. ( Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R, 2011) |
| "This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs." | 1.91 | Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital. ( Almaghaslah, D; Khaled, A; Makki, S; Nagib, R; Siddiqua, A, 2023) |
| "The sVEGFR-1 level of ESRD group was significantly higher (0." | 1.48 | Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications. ( Acar, R; Erturk, I; Ozgurtas, T; Saglam, K; Yesildal, F, 2018) |
| "Dabigatran has demonstrated similar efficacy and safety to enoxaparin for VTE prevention in patients undergoing hip and knee arthroplasty, and to warfarin for the treatment of VTE." | 1.42 | The evolving role of dabigatran etexilate in clinical practice. ( Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA, 2015) |
| "Rectus sheath hematoma is an uncommon cause of acute abdomen and is known to mimic various common surgical conditions." | 1.33 | Massive rectus sheath hematoma. ( Hamdan, K; Rajagopal, AS; Shinkfield, M; Voight, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 14 (48.28) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Sirenko, IuN | 1 |
| Sychev, OS | 1 |
| Reĭko, MN | 1 |
| Shchupak, MB | 1 |
| Sidorenko, PI | 1 |
| Camporese, G | 1 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| McKeage, K | 1 |
| Keating, GM | 1 |
| Voci, D | 3 |
| Götschi, A | 3 |
| Held, U | 3 |
| Bingisser, R | 3 |
| Colucci, G | 3 |
| Duerschmied, D | 3 |
| Fumagalli, RM | 3 |
| Gerber, B | 3 |
| Hasse, B | 3 |
| Keller, DI | 3 |
| Konstantinides, SV | 3 |
| Mach, F | 3 |
| Rampini, SK | 3 |
| Righini, M | 3 |
| Robert-Ebadi, H | 3 |
| Rosemann, T | 3 |
| Roth-Zetzsche, S | 3 |
| Sebastian, T | 3 |
| Simon, NR | 3 |
| Spirk, D | 3 |
| Stortecky, S | 3 |
| Vaisnora, L | 3 |
| Kucher, N | 3 |
| Barco, S | 3 |
| Khaled, A | 1 |
| Almaghaslah, D | 1 |
| Nagib, R | 1 |
| Makki, S | 1 |
| Siddiqua, A | 1 |
| Boari, GEM | 1 |
| Chiarini, G | 1 |
| Bonetti, S | 1 |
| Malerba, P | 1 |
| Bianco, G | 1 |
| Faustini, C | 1 |
| Braglia-Orlandini, F | 1 |
| Turini, D | 1 |
| Guarinoni, V | 1 |
| Saottini, M | 1 |
| Viola, S | 1 |
| Ferrari-Toninelli, G | 1 |
| Pasini, G | 1 |
| Mascadri, C | 1 |
| Bonzi, B | 1 |
| Desenzani, P | 1 |
| Tusi, C | 1 |
| Zanotti, E | 1 |
| Nardin, M | 1 |
| Rizzoni, D | 1 |
| Gibson, CM | 2 |
| Korjian, S | 1 |
| Chi, G | 1 |
| Daaboul, Y | 1 |
| Jain, P | 1 |
| Arbetter, D | 1 |
| Goldhaber, SZ | 1 |
| Hull, R | 1 |
| Hernandez, AF | 1 |
| Lopes, RD | 1 |
| Gold, A | 2 |
| Cohen, AT | 2 |
| Harrington, RA | 1 |
| Erturk, I | 1 |
| Yesildal, F | 1 |
| Acar, R | 1 |
| Ozgurtas, T | 1 |
| Saglam, K | 1 |
| Hellenbart, E | 1 |
| Drambarean, B | 1 |
| Lee, J | 1 |
| Nutescu, EA | 1 |
| Connolly, SJ | 1 |
| Milling, TJ | 1 |
| Eikelboom, JW | 1 |
| Curnutte, JT | 1 |
| Bronson, MD | 1 |
| Lu, G | 1 |
| Conley, PB | 1 |
| Verhamme, P | 1 |
| Schmidt, J | 1 |
| Middeldorp, S | 1 |
| Beyer-Westendorf, J | 1 |
| Albaladejo, P | 1 |
| Lopez-Sendon, J | 1 |
| Goodman, S | 1 |
| Leeds, J | 1 |
| Wiens, BL | 1 |
| Siegal, DM | 1 |
| Zotova, E | 1 |
| Meeks, B | 1 |
| Nakamya, J | 1 |
| Lim, WT | 1 |
| Crowther, M | 1 |
| Khoobiar, S | 1 |
| Mejevoi, N | 1 |
| Kaid, K | 1 |
| Boiangiu, C | 1 |
| Setty, S | 1 |
| Tanwir, A | 1 |
| Khalid, K | 1 |
| Cohen, M | 1 |
| Zeymer, U | 1 |
| Gitt, A | 1 |
| Zahn, R | 1 |
| Jünger, C | 1 |
| Bauer, T | 1 |
| Heer, T | 1 |
| Koeth, O | 1 |
| Senges, J | 1 |
| Palumbo, A | 1 |
| Cavo, M | 1 |
| Bringhen, S | 1 |
| Zamagni, E | 1 |
| Romano, A | 1 |
| Patriarca, F | 1 |
| Rossi, D | 1 |
| Gentilini, F | 1 |
| Crippa, C | 1 |
| Galli, M | 1 |
| Nozzoli, C | 1 |
| Ria, R | 1 |
| Marasca, R | 1 |
| Montefusco, V | 1 |
| Baldini, L | 1 |
| Elice, F | 1 |
| Callea, V | 1 |
| Pulini, S | 1 |
| Carella, AM | 1 |
| Zambello, R | 1 |
| Benevolo, G | 1 |
| Magarotto, V | 1 |
| Tacchetti, P | 1 |
| Pescosta, N | 1 |
| Cellini, C | 1 |
| Polloni, C | 1 |
| Evangelista, A | 1 |
| Caravita, T | 1 |
| Morabito, F | 1 |
| Offidani, M | 1 |
| Tosi, P | 1 |
| Boccadoro, M | 1 |
| Wilcox, R | 1 |
| Pendleton, RC | 1 |
| Smock, KJ | 1 |
| Rodgers, GM | 1 |
| Hoffmann, P | 1 |
| Keller, F | 1 |
| Katrancioglu, N | 1 |
| Karahan, O | 1 |
| Kilic, AT | 1 |
| Altun, A | 1 |
| Katrancioglu, O | 1 |
| Polat, ZA | 1 |
| Biteker, M | 1 |
| Tekkeşin, Aİ | 1 |
| Can, MM | 1 |
| Dayan, A | 1 |
| Ilhan, E | 1 |
| Türkmen, FM | 1 |
| Bergmann, JF | 1 |
| Mouly, S | 1 |
| Chow, SL | 1 |
| Zammit, K | 1 |
| West, K | 1 |
| Dannenhoffer, M | 1 |
| Lopez-Candales, A | 1 |
| Stellbrink, C | 1 |
| Nixdorff, U | 1 |
| Hofmann, T | 1 |
| Lehmacher, W | 1 |
| Daniel, WG | 1 |
| Hanrath, P | 1 |
| Geller, C | 1 |
| Mügge, A | 1 |
| Sehnert, W | 1 |
| Schmidt-Lucke, C | 1 |
| Schmidt-Lucke, JA | 1 |
| Chazova, IE | 1 |
| Mychka, VB | 1 |
| Mamyrbaeva, KM | 1 |
| Gornostaev, VV | 1 |
| Dvoskina, IM | 1 |
| Sergienko, VB | 1 |
| Bazinet, A | 1 |
| Almanric, K | 1 |
| Brunet, C | 1 |
| Turcotte, I | 1 |
| Martineau, J | 1 |
| Caron, S | 1 |
| Blais, N | 1 |
| Lalonde, L | 1 |
| Spinler, S | 1 |
| Rajagopal, AS | 1 |
| Shinkfield, M | 1 |
| Voight, S | 1 |
| Hamdan, K | 1 |
| Le Feuvre, C | 1 |
| Batisse, A | 1 |
| Collet, JP | 1 |
| Batisse, JP | 1 |
| Choussat, R | 1 |
| Beygui, F | 1 |
| Helft, G | 1 |
| Montalescot, G | 1 |
| Metzger, JP | 1 |
| Hunt, D | 1 |
| SUSSMAN, I | 1 |
| LYDECKER, E | 1 |
| Pautas, E | 1 |
| Siguret, V | 1 |
| d'Urso, M | 1 |
| Laurent, M | 1 |
| Gaussem, P | 1 |
| Février, M | 1 |
| Durand-Gasselin, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)[NCT02329327] | Phase 3 | 479 participants (Actual) | Interventional | 2015-04-10 | Completed | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. The change from baseline was calculated as the reduction in anti-fXa activity from baseline to the on-treatment nadir (that is, the minimum value between end of bolus and end of infusion). Percent reduction was calculated as the ratio between the maximum change from baseline and the baseline value, multiplied by 100. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| FXa Inhibitor: Apixaban | -93.3 |
| FXa Inhibitor: Rivaroxaban | -94.1 |
| FXa Inhibitor: Edoxaban | -71.3 |
| FXa Inhibitor: Enoxaparin | -75.41 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. These ratings were based on pre-specified criteria that were included in the EAC Charter. The EAC was blinded to anti-fXa activity levels. Participant results were classified as either success or failure based on the hemostatic efficacy rating (success = excellent/good, failure = poor/none). Participants rated by the EAC as non-evaluable due to administrative reasons were excluded from the analysis of hemostatic efficacy. (NCT02329327)
Timeframe: 12 Hours (post infusion)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| Andexanet: High Dose | 54 | 17 |
| Andexanet: High Dose - Additional Participant | 1 | 0 |
| Andexanet: Low Dose | 218 | 51 |
| Andexanet: Low Dose - Additional Participant | 1 | 0 |
| Bleed Type: Gastrointestinal | 61 | 13 |
| Bleed Type: Intracranial Hemorrhage | 193 | 51 |
| Bleed Type: Intracranial Hemorrhage - Additional Participants | 2 | 0 |
| Bleed Type: Other | 18 | 4 |
| FXa Inhibitor: Apixaban | 134 | 35 |
| FXa Inhibitor: Edoxaban | 22 | 6 |
| FXa Inhibitor: Enoxaparin | 14 | 2 |
| FXa Inhibitor: Rivaroxaban | 102 | 25 |
| FXa Inhibitor: Rivaroxaban - Additional Participants | 2 | 0 |
| Overall | 272 | 68 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) |
|---|---|
| Excellent/Good | |
| FXa Inhibitor: Rivaroxaban - Additional Participants | -96.3 |
This outcome measure assessed the relationship between hemostatic efficacy and anti-fXa activity in participants receiving an FXa inhibitor who had acute major bleeding. Anti-fXa activity was measured to assess the ability of andexanet to reverse the anticoagulant effect of FXa inhibitors. Baseline was defined as the last value obtained prior to the start of the andexanet bolus. Hemostatic efficacy was achieved when the body had time to produce thrombin and a subsequent clot and was rated by the EAC as: excellent; good; poor/none; not evaluable due to non-administrative reasons; not evaluable due to administrative reasons. (NCT02329327)
Timeframe: Baseline, 12 Hours (post infusion)
| Intervention | Percent Change (Median) | |
|---|---|---|
| Excellent/Good | Poor/None | |
| FXa Inhibitor: Apixaban | -93.4 | -93.3 |
| FXa Inhibitor: Edoxaban | -75.8 | -65.2 |
| FXa Inhibitor: Enoxaparin | -75.20 | -78.44 |
| FXa Inhibitor: Rivaroxaban | -94.6 | -92.4 |
6 reviews available for dalteparin and Cardiovascular Diseases
| Article | Year |
|---|---|
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug | 2009 |
Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.
Topics: Anticoagulants; Cardiovascular Diseases; Chronic Disease; Drug Administration Schedule; Fibrinolytic | 2008 |
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as | 2011 |
Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis.
Topics: Anticoagulants; Cardiovascular Diseases; Enoxaparin; Glomerular Filtration Rate; Hemorrhage; Humans; | 2012 |
Thromboprophylaxis in medical patients: focus on France.
Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Meth | 2002 |
Low-molecular-weight heparins in clinical practice.
Topics: Anticoagulants; Cardiovascular Diseases; Clinical Trials as Topic; Dalteparin; Enoxaparin; Fibrinoly | 1998 |
9 trials available for dalteparin and Cardiovascular Diseases
| Article | Year |
|---|---|
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Topics: Adult; Anticoagulants; Cardiovascular Diseases; COVID-19; Enoxaparin; Female; Humans; Male; Middle A | 2023 |
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Benzamides; Cardiovascular Diseases; Double-Blind Method | 2017 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiovascular Diseases; Enoxaparin; Factor Xa; Factor Xa In | 2016 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin | 2011 |
Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Enoxaparin; Factor Xa; Female; Hum | 2003 |
Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE)
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Drug Thera | 2004 |
Dosage of enoxaparin among obese and renal impairment patients.
Topics: Aged; Blood Coagulation Tests; Body Weight; Cardiovascular Diseases; Drug Monitoring; Enoxaparin; Fa | 2005 |
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Contrast Media; Coronary Angio | 2006 |
[Monitoring of tinzaparin in a ten day treatment dose in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Creatinine; Drug Administration Sched | 2001 |
14 other studies available for dalteparin and Cardiovascular Diseases
| Article | Year |
|---|---|
[The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology].
Topics: Anticoagulants; Cardiovascular Diseases; Combined Modality Therapy; Drug Evaluation; Heparin; Humans | 1994 |
Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Enoxaparin; Furosemide; Humans; Li | 2023 |
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Cardiovascular Diseases; Comorbidity; COV | 2020 |
Vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 in patients with end-stage renal disease. Associations with laboratory findings, comorbidities, and medications.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Cardiovascu | 2018 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinic | 2015 |
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Enoxaparin; Female; Fibrinolytic Agen | 2008 |
Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Drug Therapy, Combination; Enoxaparin; Fibr | 2009 |
Comparison of the antiangiogenic effects of heparin sodium, enoxaparin sodium, and tinzaparin sodium by using chorioallantoic membrane assay.
Topics: Angiogenesis Inhibitors; Animals; Anticoagulants; Biological Assay; Cardiovascular Diseases; Chick E | 2012 |
Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Case-Control | 2012 |
[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk].
Topics: Adult; Anticoagulants; Blood Glucose; Blood Pressure; Body Mass Index; Brain; C-Peptide; Cardiovascu | 2004 |
Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
Topics: Anticoagulants; Biomarkers; Cardiovascular Diseases; Comorbidity; Creatinine; Dose-Response Relation | 2004 |
Massive rectus sheath hematoma.
Topics: Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Enoxaparin; Epigastric Arteries; Female; Hem | 2006 |
Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Topics: Angina, Unstable; Angioplasty; Anticoagulants; Aspirin; Cardiovascular Diseases; Clinical Trials as | 2000 |
Depo-heparin for long term therapy of myocardial infarction.
Topics: Cardiovascular Diseases; Dalteparin; Heparin; Humans; Myocardial Infarction | 1952 |